Mr. Gergen joined Poseida in February 2018. From September 2016 to October 2017, Mr. Gergen was the senior vice president and chief operating officer of Halozyme, Inc. and a consultant for Halozyme from October of 2017 to February of 2018. From February 2013 until August 2016, Mr. Gergen served as executive vice president and chief operating officer at Mirati Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing a pipeline of targeted oncology products. From May 2005 to November 2012, Mr. Gergen served in senior management positions, including most recently as senior vice president, corporate development, at Amylin Pharmaceuticals, Inc., biopharmaceutical company that was focused on the development and commercialization of medicines to treat chronic diseases. From July 2003 to March 2005, Mr. Gergen served as executive vice president of CardioNet Inc., a cardiovascular diagnostic company. From June 1999 to May 2003, he served as chief financial and development officer and later as chief restructuring officer of Advanced Tissue Sciences, Inc. From August 1994 to June 1999, he held several positions at Medtronic, Inc. Mr. Gergen received a J.D. from the University of Minnesota Law School and a B.A. in business administration from Minot State University.